)
Visual
earnings real time
Xencor (XNCR) investor relations material
Xencor Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary2 Dec, 2025
Expansion into autoimmune disease
Re-entered autoimmune space with XmAb942, a high-potency, long half-life anti-TL1A antibody targeting IBD, aiming for best-in-class efficacy and less frequent dosing.
Phase I data showed >71-day half-life, sustained TL1A suppression, and strong tolerability in healthy volunteers.
XENITH-UC phase IIb study in ulcerative colitis is underway, targeting 220 patients across 150+ sites, with primary analysis at 12 weeks for clinical remission.
XmAb412, a TL1A/IL-23 bispecific, is set for first-in-human studies in 2026, aiming to combine two leading IBD mechanisms in one molecule.
XmAb657, a CD19/CD3 bispecific, opened its first study in myositis, with plans to expand indications and deliver data granularity by year-end.
Oncology pipeline progress
XmAb819, an ENPP3 x CD3 bispecific, showed a 25% response rate in heavily pretreated clear cell renal cell carcinoma patients, with plans for expansion into colorectal and lung cancers.
XmAb541, a Claudin-6 x CD3 bispecific, demonstrated early efficacy in ovarian and germ cell tumors, with three of nine responders in the highest completed cohort.
Plans to optimize XmAb541 dosing and move into late-line studies, with phase III dose selection expected next year.
Strategic partnerships and future outlook
Amgen partnership includes phase III trials for Xaluritamig in prostate cancer, with mid- to high-single digit royalties and $225M in milestones.
J&J collaboration focuses on CD28 bispecifics, leveraging orthogonal binding for improved safety and efficacy in combination therapies.
Partnerships remain central, with a strategy to advance key assets in oncology, TL1A, and B-cell depleters, and flexibility to partner or commercialize based on ROI.
Well-funded through 2028, with multiple data readouts expected in 2026 and beyond to inform future development and partnering decisions.
XmAb819's unique design and RCC patient response
How will Xencor decide on pipeline commercialization?
B-cell depleters: achieving rheumatology-friendly regimen
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Xencor earnings date
Q4 202525 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Xencor Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology to create antibody-based therapies that enhance immune responses or modulate immune activity. Xencor's pipeline includes candidates designed to target specific proteins involved in disease processes, aiming to provide more effective and durable treatments. The company is involved in both internal research and collaborations with other biopharma companies to advance its therapies through clinical trials. The company is headquartered in Monrovia, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage